- Home
- AMS vs CGTX Comparison
AMS vs CGTX Comparison
Compare AMS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- CGTX
- Stock Information
- Founded
- AMS 1980
- CGTX 2007
- Country
- AMS United States
- CGTX United States
- Employees
- AMS N/A
- CGTX N/A
- Industry
- AMS Medical Specialities
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- CGTX Health Care
- Exchange
- AMS Nasdaq
- CGTX Nasdaq
- Market Cap
- AMS 18.3M
- CGTX 20.5M
- IPO Year
- AMS N/A
- CGTX 2021
- Fundamental
- Price
- AMS $2.35
- CGTX $0.30
- Analyst Decision
- AMS
- CGTX Strong Buy
- Analyst Count
- AMS 0
- CGTX 5
- Target Price
- AMS N/A
- CGTX $5.63
- AVG Volume (30 Days)
- AMS 13.6K
- CGTX 1.9M
- Earning Date
- AMS 08-13-2025
- CGTX 08-07-2025
- Dividend Yield
- AMS N/A
- CGTX N/A
- EPS Growth
- AMS 151.01
- CGTX N/A
- EPS
- AMS 0.21
- CGTX N/A
- Revenue
- AMS $29,236,000.00
- CGTX N/A
- Revenue This Year
- AMS $23.63
- CGTX N/A
- Revenue Next Year
- AMS N/A
- CGTX N/A
- P/E Ratio
- AMS $11.30
- CGTX N/A
- Revenue Growth
- AMS 35.25
- CGTX N/A
- 52 Week Low
- AMS $2.30
- CGTX $0.22
- 52 Week High
- AMS $4.60
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- AMS 46.47
- CGTX 48.87
- Support Level
- AMS $2.30
- CGTX $0.25
- Resistance Level
- AMS $2.50
- CGTX $0.33
- Average True Range (ATR)
- AMS 0.12
- CGTX 0.03
- MACD
- AMS 0.01
- CGTX 0.00
- Stochastic Oscillator
- AMS 32.36
- CGTX 58.69
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.